The Diabetes Control and Complications Trial: The gift that keeps giving

Nature Reviews Endocrinology

Volumn 5, Issue 10, 2009, Pages 537-545

  Kilpatrick, Eric S ^a   Rigby, Alan S ^a   Atkin, Stephen L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

COGNITION; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC RETINOPATHY; DIET; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MICROVASCULARIZATION; NEUROPATHY; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; FEMALE; HUMANS; HYPOGLYCEMIA; MALE; PREGNANCY;

EID: 70349442506     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2009.179     Document Type: Review

References (67)

1. [no authors listed] The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes 35, 530-545 (1986).
2. Goldstein, D. E., Little, R. R., wiedmeyer, H. M., England, J. D. & McKenzie, E. M. Glycated hemoglobin: methodologies and clinical applications. Clin. Chem. 32, B64-B70 (1986).
3. Lauritzen, T., Frost-Larsen, K., Larsen, H. & Deckert, T. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulindependent diabetics. Lancet 1, 200-204 (1983).
4. [no authors listed] Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. The Kroc Collaborative Study Group. N. Engl. J. Med. 311, 365-372 (1984).
5. Dahl-Jørgensen, K., Brinchmann-Hansen, O., Hanssen, K. F., Sandvik, L. & Aagenaes, O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br. Med. J. (Clin. Res. Ed.) 290, 811-815 (1985).
6. Lawson, P. M. et al. Continuous subcutaneous insulin infusion (CSII) does not prevent progression of proliferative and preproliferative retinopathy. Br. J. Ophthalmol. 66, 762-766 (1982).
7. van Ballegooie, E. et al. Rapid deterioration of diabetic retinopathy during treatment with continuous subcutaneous insulin infusion. Diabetes Care 7, 236-242 (1984). (Pubitemid 14105304)
8. Keen, H. Normoglycaemic re-entry and diabetic complications. Diabet. Med. 1, 85-87 (1984).
9. [no authors listed] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837-853 (1998).
10. [no authors listed] Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854-865 (1998).
11. [no authors listed] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The Diabetes Control and Complications Trial Research Group. Diabetes Care 10, 1-19 (1987).
12. [no authors listed] Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am. J. Med. 90, 450-459 (1991).
13. [no authors listed] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 329, 977-986 (1993).
14. [no authors listed] The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45, 1289-1298 (1996).
15. [no authors listed] Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Ophthalmology 102, 647-661 (1995).
16. [no authors listed] Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch. Ophthalmol. 116, 874-886 (1998).
17. [no authors listed] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial (DCCT) Research Group. Kidney Int. 47, 1703-1720 (1995).
18. [no authors listed] Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes 37, 476-481 (1988).
19. [no authors listed] The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann. Intern. Med. 122, 561-568 (1995).
20. [no authors listed] Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 46, 271-286 (1997).
21. [no authors listed] Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am. J. Cardiol. 75, 894-903 (1995).
22. The Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 23, 1084-1091 (2000).
23. Delahanty, L. M. et al. Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. Am. J. Clin. Nutr. 89, 518-524 (2009).
24. [no authors listed] Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22, 99-111 (1999).
25. writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287, 2563-2569 (2002).
26. white, N. H. et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch. Ophthalmol. 126, 1707-1715 (2008).
27. Martin, C. L. et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 29, 340-344 (2006).
28. [no authors listed] Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Diabetes 48, 383-390 (1999).
29. Nathan, D. M. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643-2653 (2005).
30. [no authors listed] The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44, 968-983 (1995).
31. Ceriello, A. et al. Evidence for a cellular "memory" of hyperglycemic stress [abstract]. Diabetes 54 (Suppl. 1), A54 (2005).
32. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577-1589 (2008).
33. Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. & Matthews, D. R. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med. 359, 1565-1576 (2008).
34. The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Study Research Group et al. Longterm effect of diabetes and its treatment on cognitive function. N. Engl. J. Med. 356, 1842-1852 (2007).
35. Musen, G. et al. Impact of diabetes and its treatment on cognitive function among adolescents who participated in the Diabetes Control and Complications Trial. Diabetes Care 31, 1933-1938 (2008).
36. DCCT/EDIC General Description. NIDDK Central Repository [online] https://www.niddkrepository. org/niddk/jsp/public/EDIC/EDICDesc.jsp
37. McCarter, R. J., Hempe, J. M., Gomez, R. & Chalew, S. A. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 27, 1259-1264 (2004).
38. Lachin, J. M., Genuth, S., Nathan, D. M. & Rutledge, B. N. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. Diabetes 56, 1913-1921 (2007).
39. Kilpatrick, E. S., Rigby, A. S. & Atkin, S. L. Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 51, 365-371 (2008).
40. Hirsch, I. B. & Brownlee, M. Should minimal blood glucose variability become the gold standard of glycemic control? J. Diabetes Complications 19, 178-181 (2005).
41. Service, F. J. & O'Brien, P. C. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 44, 1215-1220 (2001).
42. Kilpatrick, E. S., Rigby, A. S. & Atkin, S. L. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29, 1486-1490 (2006).
43. Kilpatrick, E. S., Rigby, A. S. & Atkin, S. L. variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin. Chem. 53, 897-901 (2007).
44. Lachin, J. M. et al. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial- revisited. Diabetes 57, 995-1001 (2008).
45. Kilpatrick, E. S., Rigby, A. S., Goode, K. & Atkin, S. L. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 50, 2553-2561 (2007).
46. [no authors listed] Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 46, 1829-1839 (1997).
47. Boright, A. P. et al. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 54, 1238-1244 (2005).
48. Pezzolesi, M. G. et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes mellitus. Diabetes 58, 1403-1410 (2009).
49. Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615-1625 (2005).
50. Monnier, v. M. et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 48, 870-880 (1999).
51. Genuth, S. et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54, 3103-3111 (2005).
52. Colhoun, H. M. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685-696 (2004).
53. [no authors listed] Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT Research Group. Diabetes Care 15, 886-894 (1992).
54. Jenkins, A. J. et al. Serum lipoproteins in the diabetes control and complications trial/ epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care 26, 810-818 (2003).
55. Lyons, T. J. et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest. Ophthalmol. Vis. Sci. 45, 910-918 (2004).
56. Jenkins, A. J. et al. Lipoproteins in the DCCT/ EDIC cohort: associations with diabetic nephropathy. Kidney Int. 64, 817-828 (2003).
57. Nathan, D. M. et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N. Engl. J. Med. 348, 2294-2303 (2003).
58. Lyons, T. J. et al. Nuclear magnetic resonancedetermined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet. Med. 23, 955-966 (2006).
59. Ridker, P. M., Rifai, N., Rose, L., Buring, J. E. & Cook, N. R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347, 1557-1565 (2002).
60. Schaumberg, D. A. et al. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation 111, 2446-2453 (2005).
61. Jenkins, A. J. et al. Cross-sectional associations C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J. Diabetes Complications 22, 153-163 (2008).
62. Nathan, D. M. et al. Translating the A1c assay into estimated average glucose values. Diabetes Care 31, 1473-1478 (2008).
63. Rohlfing, C. L. et al. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 25, 275-278 (2002).
64. McCarter, R. J., Hempe, J. M. & Chalew, S. A. Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial. Diabetes Care 29, 352-355 (2006).
65. Kilpatrick, E. S., Rigby, A. S. & Atkin, S. L. A1c variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 31, 2198-2202 (2008).
66. Little, R. R. et al. The national glycohemoglobin standardization program: a five-year progress report. Clin. Chem. 47, 1985-1992 (2001).
67. weykamp, C. et al. The IFCC reference measurement system for HbA1c: a 6-year progress report. Clin. Chem. 54, 240-248 (2008).